Immunotherapy: Opportunities, risks and future perspectives

Martin Hildebrandt, Karl Peggs, Lutz Uharek, Catherine M. Bollard, Helen E. Heslop

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

This review is intended to reflect upon the current status and perspectives of cell-based immunotherapy at a time when the promise of extensive pre-clinical research has been translated into encouraging clinical responses. However, some of these have also been complicated by significant adverse reactions. As the field moves towards definitive late stage trials, with a growing interest from pharmaceutical companies, we realize that novel cell therapy strategies pose questions that are familiar to traditional drug development, along with new considerations due to the potential of T cells to persist long term and to expand after adoptive transfer. These questions address the safety of the product, the efficacy, the mode of action, and the anticipation of risks. From different perspectives, we intend to address exciting opportunities and safety concerns in current concepts of cellular immunotherapy.

Original languageEnglish (US)
Pages (from-to)S120-S129
JournalCytotherapy
Volume16
Issue number4
DOIs
StatePublished - Apr 1 2014

Keywords

  • Clinical trials
  • Gene therapy
  • Immunotherapy
  • Safety
  • T cell receptor
  • Treatment efficacy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Fingerprint Dive into the research topics of 'Immunotherapy: Opportunities, risks and future perspectives'. Together they form a unique fingerprint.

Cite this